Table 1.

Antiproliferative effect of LIMKi on prostate cancer cell lines. All cell lines were treated with half-log serial dilutions of LIMKi for 72 hours. EC50 values were measured from dose–response curves from three independent experiments performed in triplicates

LIMKi EC50P value, F test
Cell line(μmol/L)(compared with LNCaP)
LNCaP1.33
CWR226.97<0.0001
LNCaP-AI11.11<0.0001
DU14511.46<0.0001
PC312.68<0.0001